Merck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after being turned down by the US regulator. The US approval for relapsing/remitting and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results